Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study

Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study

As one of the first Direct Acting Antivirals (DAA), the protease inhibitor Telaprevir (TVR) was available in the European Union from 9/2011 until 9/2016 as a new treatment option for chronic Hepatitis C.Aim. To assess the implementation of therapy stopping rules or shortening of the treatment and th...

Full description

Saved in:
Bibliographic Details
Main Authors: T. Berg, P. Buggisch, D. Hueppe, S. Mauss, H. Wedemeyer, G. Teuber, T. Lutz, K. Stein, S. Wegner, H. Hinrichsen
Format: Article
Language:Russian
Published: Gastro LLC 2019-01-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
hepatitis c
direct acting antivirals (daa)
stopping rule
shortening of treatment
sustained virological response (svr)
Online Access:https://www.gastro-j.ru/jour/article/view/295
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items